Hot topics | Coronavirus pandemic

Nordic Nanovector Appoints Experienced Pharmaceutical Business Leader Erik Skullerud as Chief Executive Officer

Nordic Nanovector Appoints Experienced Pharmaceutical Business Leader Erik Skullerud as Chief Executive Officer

- Nordic Nanovector ASA (OSE: NANOV) announces the appointment of Erik Skullerud as Chief Executive Officer (CEO). He is going to take up the position on 20 September 2021 and will be based in the company's branch of Zug, Switzerland, splitting his time between Zug and Nordic Nanovector'' s head office in Oslo.

Mr Skullerud joined the company from Element Consulting GmbH, a global focused boutique consultancy firm specializing in life science where he was co-founder and managing partner.

Before founding Element Consulting, Mr. Skullerud spent 25 years in the biopharma industry and became responsible for global sales and marketing. After more than 15 years at Amgen, his most recent role was as Marketing Director Europe Oncology/ Hematology. Prior to that, he worked for Bayer Pharma for seven years, most recently as a Product Group Manager for Cardiovascular/Diabetic Scandinavia.

Mr. Skullerud has launched numerous highly innovative products in therapeutic areas such as oncology, haematology and cardiology, and is a highly-known businessman in the EU, Asian and US markets. As a consultant, he worked with many of the world's leading pharmaceutical and biotech companies, and small, highly specialised start-ups on projects ranging from corporate strategy to mid-stage launch and commercialization to late

Mr. Skullerud is Norwegian and Swiss resident. He has a BSc in Marketing, Finance and Management from the Gothenburg Business School, University of Gotheborg and was guest speaker of the INSEAD MBA program, Paris, France.

"I'm very pleased that Erik has agreed to join Nordic Nanovector." As soon as we become a larger, more valuable business, Betalutin will offer maximum commercial potential. His commercial experience and knowledge of the oncology/haematology space will be crucial to our growth to redevelop I would like to thank Malene Brondberg for his resignation over the last few months as interim CEO, a time in which the company has made measurable progress in achieving its key objectives. Malene will continue his job as CFO.

Mr. Skullerud added: "I really expect this new role in Nordic Nanovector. I believe the company's experience in strategy, commercialisation, sales and marketing can help achieve the next important stage of its development, as we work to bring Betalutin to patients for the first time, a key step in

The company's annual report for 2020 shows that when he joins Nordic Nanovector, Mr. Skullerud will be granted 350 000 PSUs (performance share units). For further information on the PPUs and the

For more information, please contact: IR enquiries are subject to a request for ir. Jan H. Egberts, chairman of Nordic NanovectorTel: +31 614672518Email: [email protected]

Media questions asks a media inquiry. Mark Swallow/Frazer Hall/David Dible (MEDiSTRAVA Consulting)Tel: +44 203 926 8535Email: [email protected]

About Nordic Nanovector: Nordic Nanovector is committed to developing and delivering innovative therapies to patients to meet their medical needs and advance cancer care. The Company hopes to become a leader in the development of targeted therapies for haematological cancer. Betalutin is the novel CD37-targeting antibody-radionuclide-conjugate that is designed to improve the treatment of non-Hodgkin's lymphoma. NHL is an indication with a substantial unmet medical need, bringing the current market forecast to reach almost $2 billion by 2028. Nordic nanovector retains the global marketing rights of Betalutin and plans to participate actively in the commercialisation of betalutinic in US and other major markets.

More information can be found at

Forward-looking statements are forward-facing statements. There are certain forward-looking statements contained in this press release. These statements are based on management's current expectations and subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will happen in the future and which, by their nature, will impact on Nordic Nanovector "anticipates", "assumes","believes, "can",", or "estimate",'s "expect",/or "deplore", / "forecasts," These forward-looking statements aren't historical facts. There are several factors that could lead to actual results and developments to differ materially from those expressed or implied in the forward-looking statements. The challenges that could cause these differences include, but are not limited to, the risks and uncertainties associated with implementation of Nordic Nanovector's strategy, a competitive position and reversibility, new products and new technologies in the future No assurance can be given that such expectations will prove to be true. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether due to new information or future events.

These information have the duty of disclosure under section 4-2 and 5-12 of the Securities Trading Act. Cision brought this information to you by Cission. Cised has delivered this report to the people who have contacted us.

-,c3415106 / nonc-fdd

Nordic nanovector SOURCE Nordic Nanovecteur SURCE NanoVictorian Nanovervektor SHERCE SORCE.

You may also like: